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Abstract
Background: A Phase Ia trial in European volunteers of the candidate vaccine merozoite surface protein 3 (MSP3), a
Plasmodium falciparum blood stage membrane, showed that it induces biologically active antibodies able to achieve
parasite killing in vitro, while a phase Ib trial in semi-immune adult volunteers in Burkina Faso confirmed that the vaccine
was safe. The aim of this study was to assess the safety and immunogenicity of this vaccine candidate in children aged 12–
24 months living in malaria endemic area of Burkina Faso.
Methods: The study was a double-blind, randomized, controlled, dose escalation phase Ib trial, designed to assess the
safety, reactogenicity and immunogenicity of three doses of either 15 or 30 mg of MSP3-LSP adsorbed on aluminum
hydroxide in 45 children 12 to 24 months of age randomized into three equal groups. Each group received 3 vaccine doses
(on days 0, 28 and 56) of either 15 mg of MSP3-LSP, 30 mg of MSP3-LSP or of the Engerix B hepatitis B vaccine. Children were
visited at home daily for the 6 days following each vaccination to solicit symptoms which might be related to vaccination.
Serious adverse events occurring during the study period (1 year) were recorded. Antibody responses to MSP3-LSP were
measured on days 0, 28, 56 and 84.
Results: All 45 enrolled children received three MSP3 vaccine doses. No serious adverse events were reported. Most of the
adverse events reported were mild to moderate in severity. The only reported local symptoms with grade 3 severity were
swelling and induration, with an apparently dose related response. All grade 3 adverse events resolved without any
sequelae. Both MSP3 doses regimens were able to elicit high levels of anti-MSP3 specific IgG1 and IgG3 antibodies in the
volunteers with very little or no increase in IgG2, IgG4 and IgM classes: i.e. vaccination induced predominantly the isotypes
involved in the monocyte-dependent mechanism of P. falciparum parasite-killing.
Conclusion: Our results support the promise of MSP3-LSP as a malaria vaccine candidate, both in terms of tolerability and of
immunogenicity. Further assessment of the efficacy of this vaccine is recommended.
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Introduction
The burden of malaria remains high in sub-Saharan countries
despite the extensive deployment of existing control tools, such as
insecticide-treated materials, intermittent preventive treatment,
and artemisinin-based combination therapy (ACT) [1]. The
development of an effective malaria vaccine could greatly
contribute to disease control. In recent years, the effort to develop
an effective malaria vaccine has resulted in a number of malaria
vaccine candidates reaching the stage of testing in malaria-exposed
populations. Most of the tested vaccines are either pre-erythrocytic
or blood-stage malaria vaccine candidates.
One of the leading blood stage candidates is the merozoite
surface protein 3 (MSP3), an antigen which is associated with the
membrane of the free blood stage parasite. While most other
vaccine candidates have been identified by experiments performed
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in experimental malaria models, MSP3 was identified by a clinical
experiment in humans. The protection afforded by passive transfer
of IgG from African adults into infected Thai children identified
the cooperation of IgG with blood monocytes as a main defense
mechanism in human beings in an antibody dependent, cellular
inhibitory fashion (ADCI). Thereafter, the ADCI mechanism was
used to screen a genome-wide expression library and identified
MSP3 as the main target of antibodies mediating the monocyte-
dependent P. falciparum killing effect. The monocyte-dependent
mechanism implies that only the cytophilic classes of IgG, namely
IgG1and IgG3, are important in mediating the effects, and
epidemiological studies have confirmed that protection is associ-
ated with such cytophilic responses against MSP3 [2–5]. In
malaria endemic areas, cytophilic anti-MSP3 and anti-crude
P.falciparum lysates antibodies (IgG1 and IgG3) are dominant in
clinically protected individuals, whereas non-cytophilic antibodies
(IgG2 and IgM) predominate in clinically susceptible individuals
[2,6–8]. Finally, in contrast to most vaccine candidates and the N-
terminal region of MSP3 [9], the C-terminal region of MSP3 is
highly conserved from one parasite isolate to the other.
A long polypeptide chain (95 amino acids), derived from the
highly conserved MSP3 C-terminal region, and produced in a
single step by solid-phase synthesis (MSP3 long synthetic peptide
(MSP3-LSP)), was tested in European, malaria-naı¨ve volunteers
and shown to be safe and immunogenic, inducing strong T-helper
1 and B-cell responses [10]. The induced antibodies were
predominantly cytophilic and were able to inhibit P. falciparum
erythrocytic growth in a monocyte dependent manner, under both
in vitro and in vivo conditions [11]. A subsequent phase Ib trial in
semi-immune adult volunteers, living in an area of Burkina Faso
where malaria transmission is seasonally hyperendemic, found the
vaccine to be safe at a dose of 30 mg, with less local reactogenicity
in P. falciparum exposed individuals than was observed after the
second and third doses in naı¨ve volunteers [7]. This trial also
suggested that the vaccine is able to stimulate cell-mediated
immunity in individuals with some pre-existing immunity.
However, no detectable humoral immune response was induced
by the MSP3-LSP vaccine [12]. Although inducing a moderate
cell-mediated immune response in adults with some pre-existing
immunity, MSP3-LSP was well tolerated and met the preset GO
criteria. Based on these findings, a phase 1b dose selection study
was conducted in Burkina Faso to assess the safety, reactogenicity
and immunogenicity of the vaccine in healthy children aged 1–2
years at enrolment.
Materials and Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Ethic Statement
The trial protocol was approved by the national ethical
committee of Burkina Faso and by the ethics committee of the
London School of Hygiene and Tropical Medicine. The trial was
conducted in compliance with principles set out by the
International Conference on Harmonization Good Clinical
Practices, the Declaration of Helsinki and the regulatory
requirements of Burkina Faso.
Authorization to conduct the study was sought from the relevant
administrative and health authorities in the study area. The assent
of the community was obtained through a series of meetings with
community opinion leaders and senior members. Individual
written informed consent was obtained from all children’s parents
or legal representatives, in the presence of an impartial witness for
illiterate parents/legal representatives.
The conduct of the study was monitored by the sponsor, African
Malaria Network Trust (AMANET).
The study was overseen by a Data Safety Monitoring Board
(DSMB), operating under a charter constituted by the sponsor.
The DSMB and the local safety monitor reviewed the cumulative
safety data and provided the investigators, through the sponsor,
with a written authorization to proceed to the next vaccination
and dose escalation at each stage.
Study site
The trial was conducted at the Centre National de Recherche et
Formation sur le Paludisme (CNRFP) malaria vaccine clinical trials
center located in the village of Balonghin, in Sapone´ health district,
50 km southeast of Ouagadougou, the capital city of Burkina Faso.
The area has been described elsewhere [12–13]. Malaria in this area
is hyperendemic and transmission is seasonal. The climate is
characteristic of the Sudanese savannah, with two distinct seasons: a
dry season from November to May and a rainy season from June to
October. The entomological inoculation rate in the area is
estimated at less than one and more than 40 infective bites/
person/month during the dry and rainy seasons, respectively. P.
falciparum is the predominant malaria parasite, accounting for more
than 95% of infections in children below the age of 5 during the
high transmission season. The use of preventive measures
(insecticide impregnated nets and indoor residual spraying) has
been uncommon in the area.
The clinical trial center is equipped and staffed to undertake
clinical trial phases 1b through 2b in compliance with national and
international standards and requirements.
Sapone´ district hospital and the Pediatric Teaching Hospital in
Ouagadougou both serve as referral hospitals for study partici-
pants requiring specialized care.
Study design
The study was a double-blind, randomized, controlled, dose
escalation phase Ib trial (www.clinicaltrials.gov NCT00452088)
designed to assess the safety, reactogenicity and immunogenicity of
three injections of either 15 mg or 30 mg of MSP3-LSP adsorbed
on aluminum hydroxide in children 12 to 24 months of age. Trial
participants were recruited among healthy children living in four
villages within Sapone´ health district. The study duration was one
year for enrolled participants.
Screening and enrollment of study participants
A list of potentially eligible children was drawn from the
Demographic Surveillance System (DSS) database run by the CNRFP
since 2005 in the study area. The parents of these children were invited
to the research center to discuss the trial, to obtain informed consent and
for screening procedures if they consented to allow their child to
participate in the study. Children were eligible for inclusion in the trial if
they were found to be healthy after a general medical examination, if
their parents indicated their intention to remain resident in the village for
the study duration (12 months) and if their parents gave written informed
consent. The first 45 children meeting the inclusion and exclusion
criteria (Box S1) were enrolled, assigned a unique identification number
and given an identity card to assist in correct identification.
The study vaccines
The MSP3-LSP vaccine is a long synthetic peptide, produced
by SYNPROSIS in France, and containing the amino-acid
sequence 154–249 of the P.falciparum merozoite surface protein-
MSP3 LSP Safety/Immunogenicity
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3. It is 98.5% pure, very stable over time and underwent a full
quality control process, including an assessment of potency,
antigen content and conformity to specifications by HPLC and
mass-spectrometry, one month before being employed for
vaccination.
The vaccine was available in a multi-dose vial in lyophilized
form. Prior to administration the vaccine was reconstituted in
compliance with the Manufacturer’s Standard Operating Proce-
dure, and adjuvanted with aluminum hydroxide. Participants
randomized to both MSP3 groups (MSP3-LSP 30 mg and MSP3-
LSP 15 mg) received 0.5 mL of the reconstituted vaccine at each
vaccination.
ENGERIX-BH [Hepatitis B Vaccine (Recombinant)] vaccine is
manufactured by GlaxoSmithKline Biologicals. It contains
purified viral surface antigen expressed in Saccharomyces cerevisiae
and contains no more than 5% yeast protein. ENGERIX-BH was
supplied as a sterile suspension, using the same adjuvant as MSP3-
LSP (aluminum hydroxide), in a pre-filled syringe for intramus-
cular administration.
Each child in the comparator group received 0.5 mL of
ENGERIX-BH containing 10 mg of the hepatitis B surface antigen
at each vaccination.
Both vaccines were administered by the subcutaneous route on
days 0, 28, and 56 in alternating arms in the deltoid region.
Immunizations were performed in 2007 from 26th June to 11th
July (the beginning of malaria high transmission season) for the 1st
dose, 24th July to 11th August for the 2nd dose and 21st August to
11th September (the peak of malaria high transmission season) for
the 3rd dose.
With Engerix BH, subcutaneous rather than intramuscular
administration may result in lower anti-HBs antibodies GMT;
however, a blood sample was taken at 6 months after the first dose
to identify children who had not developed protective levels of
antibodies. These were revaccinated with intramuscular injections
at the same time as the MSP3-LSP recipients at the end of the
study.
Assessment of study endpoints
Safety and reactogenicity. At each vaccination visit,
children underwent a physical examination before receiving the
injection. Following each vaccination, the participants remained in
the research center for at least one hour to assess immediate
adverse events. They were then visited at home on each of the next
6 days after each dose to record any solicited or unsolicited local
and systemic reactions. For the first dose, the last (day 6)
evaluation was done at the research center.
Solicited local adverse events at the injection site included pain,
swelling, induration, pruritus and erythema. Solicited systemic
reactions included fever, loss of appetite, drowsiness and
irritability/fussiness.
Any other symptoms not included in the targeted symptoms list above
were recorded as non-solicited symptoms by the investigators.
An intensity grading scale was used to grade the severity of the
adverse events. Severity of injection site reactions (other than pain
and pruritus) was graded based on the measurement of the greatest
surface diameter in mm. Grading was as follows: 0 = absent,
1 = 0–5 mm, 2 =$5–20 mm, 3 =.20 mm. Axillary temperature
was measured using a digital thermometer and fever grading was
done as follows: 0 =,37.5uC, 1 = 37.5–38uC, 2 = 38.1uC–39uC,
3 =.39uC.
Pain, pruritus, and other solicited and unsolicited systemic
reactions were graded as follows: 0 = absent/none, 1 = easily
tolerated, 2 = interferes with normal activity, 3 = prevents normal
daily activities.
Adverse events meeting one of the criteria for seriousness (death,
life-threatening, requiring hospitalization) were reported as serious
adverse events.
Venous blood samples were obtained at screening and on days
0, 6, 28, 56, and 84 to monitor the biological safety of the
candidate vaccine. Hematological [hemoglobin, hematocrit,
platelets, red blood cells (RBC) and white blood cells (WBC)],
and biochemical [creatinine, total bilirubin, and the liver enzymes
aspartate aminotransferase (ASAT) and alanine aminotransferase
(ALAT)] parameters were assessed. The local laboratory refer-
ences ranges for children aged from 12–24 months are presented
in Box S2. A blood smear was prepared and a rapid diagnostic test
for malaria was performed if a trial participant presented with an
axillary temperature $37.5uC or history of fever within the last
24 hours. The rapid diagnostic test results were used to guide
prompt treatment while awaiting the results of the slide
examination. Malaria episodes were treated with CoartemH
according to the national guidelines for care in Burkina Faso.
All adverse events were followed up to resolution.
Immunological endpoints. Humoral immune responses on
days 0, 28, 56, and 84 were evaluated using whole blood samples
collected using heparin as an anticoagulant (VF-109SHL, Terumo
Europe n.v.).
MSP3-LSP and MSP3 overlapping Peptides
We studied immunological responses to the vaccine peptide
MSP3-LSP which corresponds to a fully conserved region covering
amino acids 181–276 (product number 00FS021#1B, Dictagene,
Epalinges, CH) of the C-terminal region of MSP3 (386 amino acids
long) from the P. falciparum strain Fc27 [14]. The sequence of the
MSP3-LSP peptide is: RKTKEYAEKAKNAYEKAKNAYQ-
KANQAVLKAKEASSYDYILGWEFGGGVP EHKKEENML-
SHLYVSSKDKENISKENDDVLDEKEEEAEETEEEELE.
This peptide was synthesized, purified, bottled and lyophilized
following good laboratory practices (GLP).
Assessment of antibody responses
MSP3-LSP specific IgG, IgM and IgG1, IgG2, IgG3 and IgG4
subclass concentrations were measured by ELISA. The ELISA
was done according to the Afro Immuno Assay standard operating
procedure (SOP number AIA-007-03) [12–13]. In brief, microtiter
plates (NUNC – Maxisorp F 96 439454)) were coated with the
appropriate synthetic peptide (10 mg/ml concentration), incubated
overnight at 4uC, and blocked with 3% milk powder in PBS-
Tween 20 for 1 h. Plasma samples diluted 1:200 (IgG and IgM) or
1:25 (IgG subclasses) were added in duplicate and incubated at
room temperature for 2 h. Plates were washed 4 times between
each step. The antibody was detected using either peroxidase
conjugated goat anti-human IgG or IgM (secondary antibody
Caltag – H10007, H 15007). For IgG subclasses, the secondary
antibody was a mouse anti-human monoclonal IgG subclass (clone
NL16, Boehringer for IgG1, clone HP-6002 Sigma I-9513 for
IgG2; Sky Bio, M08011, clone ZG4 for IgG3 and Sky Bio,
M11014, clone RJ4 for IgG4). The antibody binding was revealed
using peroxidase conjugated goat anti-mouse IgG. The subclass
specific reagents used had been previously selected on the basis of
low cross reactivities among themselves, and ability to faithfully
react with African heavy chains dominant allotypes [15].
Bound secondary antibodies for IgG and IgM, and a third
antibody group for IgG subclasses were quantified using ready-to-
use TMB (3,39, 5,59-Tetramethylbenzidine) substrate. The optical
density (OD) was read at 450 nm with a reference at 620 nm, and
the OD value of the test-sample was converted into arbitrary units
(AU) by means of a standard curve on each plate.
MSP3 LSP Safety/Immunogenicity
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A pool of Burkinabe positive samples was used as a positive
control and Danish plasma samples kindly provided by Michael
Theisen from Statens Serum Institute (Copenhagen, Denmark) as negative
controls.
Randomization
The study participants were randomized to receive either MSP3-
LSP at one of two doses (30 mg or 15 mg) or the control vaccine
(Engerix B).
At the beginning of the study, the first group (22 children) was
randomized to receive either 15 mg of MSP3-LSP (N = 15) or 10 mg of
Engerix B (N = 7). Fourteen days after the first child from this group was
immunized, a second group of 23 children was randomized to receive
either 30 mg of MSP3-LSP (N = 15) or Engerix B (N = 8). Thus 15
children were randomized to each study arm.
Randomization codes were independently created by the study
statistician and participants were randomly assigned treatment
numbers upon presentation for the first dose of vaccine.
A copy of the randomization list was given to the pharmacist in
charge of the vaccine preparation and to the local safety monitor
appointed by the sponsor.
Blinding
The study was a double blind trial with the vaccine recipient
and their parent(s)/guardian(s), as well as those responsible for the
evaluation of safety and immunogenicity endpoints, unaware of
the treatment assignment of each study participant until the end of
the study. The only study personnel aware of the vaccine
assignment were those responsible for the storage and preparation
of vaccines, and they did not play any other role in the study.
Since the appearance of the two vaccines was different, opaque
tape was placed over the syringes to prevent the investigators from
seeing their contents.
Unblinding of the investigators occurred once the study data up
to day 84 had been entered and the database locked.
Statistical methods
The sample size was based on the safety endpoints. With 14
children completing follow-up in each MSP3 arm, (15 mg and
30 mg) the study had 90% power to detect at least one MSP3
vaccinated individual with a systemic reaction (or a serious adverse
event) if the underlying risk of such an event was 15% or more.
One additional subject per arm was included to ensure adequate
Figure 1. Trial profile.
doi:10.1371/journal.pone.0007549.g001
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sample size in case of dropout for any reason. Thus, 45
participants in total were recruited (15 receiving MSP-LSP
15 mg, 15 receiving MSP-LSP 30 mg, 15 receiving Engerix BH).
A statistical analysis plan was established for the trial. All original
data were transcribed from source documents to case report forms
which were counterchecked before computer entry. Descriptive
analyses were performed using STATA version 10 (College Station,
TX, USA). Given the multiplicity of endpoints considered and the
small sample size, formal statistical tests were not used to compare
vaccine groups. Geometric mean concentrations of anti-MSP3-LSP
antibodies and 95% confidence intervals were calculated.
Results
Based on the age criterion, 110 children were invited for
screening, 59 of whom were eligible. Of these, the first 45 children
Table 1. Baseline characteristics of the study participants at enrollment within each vaccine group.
Characteristics MSP3 (15 mg) (mean6SD) MSP3 (30 mg) (mean6SD) Engerix B (mean6SD)
Number randomized 15 15 15
Age (months) 18.863.6 17.463.2 18.063.4
Weight (Kg) 10.061.4 9.361.0 9.060.9
Height (Cm) 79.764.8 77.163.9 77.564.4
RBC (106/mL) 4.860.7 4.760.7 4. 660.7
WBC (103/mL) 11.362.2 10.762.6 11.061.8
Hemoglobin (g/dL) 9.861.0 10.161.1 10.161.1
Hematocrit (%) 30.962.7 31.563.3 31.762.9
Platelets (103/mL) 404.56173.7 323.96135.8 322.26128.7
Creatinine (mmol/L) 40.166.1 39.566.2 39.465.9
ASAT (U/L) 59.1610.7 53.3616.6 52.1621.8
ALAT (U/L) 32.766.14 37.869.0 40.869.6
Total bilirubin (mmol/L) 7.463.6 6.862.5 7.163.7
doi:10.1371/journal.pone.0007549.t001
Table 2. Incidence of injection site solicited adverse events according to vaccine groups.
Dose 1 Dose 2 Dose 3
Events Intensity
MSP3 (15 mg)
N=15
MSP3 (30 mg)
N=15
Engerix B
N=15
MSP3 (15 mg)
N=15
MSP3 (30 mg)
N=15
Engerix B
N=15
MSP3 (15 mg)
N=15
MSP3 (30 mg)
N=15
Engerix B
N=15
Pain
Any 12 12 2 9 8 2 6 7 1
Grade 1 12 10 2 8 8 2 6 7 1
Grade 2 0 2 0 1 0 0 0 0 0
Grade 3 0 0 0 0 0 0 0 0 0
Swelling
Any 14 11 5 5 10 2 11 8 3
Grade 1 0 1 0 0 0 0 0 0 0
Grade 2 9 8 4 4 1 1 5 1 1
Grade 3 5 3 1 1 9 1 6 7 2
Induration
Any 13 14 8 15 12 7 15 15 10
Grade 1 0 0 0 0 0 0 0 0 0
Grade 2 11 13 8 10 1 6 6 1 5
Grade 3 2 1 0 5 11 1 9 14 5
Erythema
Any 0 1 1 0 0 2 0 0 1
Grade 1 0 1 0 0 0 1 0 0 0
Grade 2 0 0 1 0 0 1 0 0 1
Grade 3 0 0 0 0 0 0 0 0 0
doi:10.1371/journal.pone.0007549.t002
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coming on the day of vaccination were enrolled. Common reasons
for exclusion included moderate malnutrition (n = 27) and the
following biological abnormalities (n = 16): anemia, high value of
ASAT and leukocytosis. Fourteen eligible subjects were not
enrolled since the target sample size had been achieved.
All participants received three doses of their allotted vaccine and
completed follow up to day 84. No dropouts were recorded and
there were no withdrawals due to vaccine adverse effects (Figure 1).
The baseline characteristics of the three vaccine groups were
broadly similar (Table 1).
Safety
The vaccines were well tolerated. No serious adverse events
were seen. The incidence of solicited injection site reactions within
the 7 day follow up period after each vaccination is reported in
Table 2. The most common local reactions were pain, swelling
and induration. Children in both MSP3-LSP groups experienced
more local symptoms than those who received the control vaccine.
Overall, local reactions were no more common in the MSP3-LSP
30 mg than in the MSP3-LSP 15 mg group. Symptoms of grade 3
severity were only reported for swelling and induration and were
more common in the MSP3-LSP vaccine group after the second
and third vaccinations (Table 2). After the second vaccination
most of the volunteers (9/15) in the 30 mg group experienced
grade 3 severity swelling, while only 1 volunteer (1/15) in each of
15 mg and Engerix groups had a similar reaction. At the third dose
7 and 6 children respectively in the MSP3 groups (30 and 15 mg)
had grade 3 swelling compared to 2 children in the Engerix group.
The majority of the MSP3-LSP 30 mg group had grade 3
induration at the injection site after the second (11/15) and the
third (14/15) doses. Grade 3 induration events were less common
in the MSP3-LSP (15 mg) and Engerix groups. All grade 3 adverse
events resolved without any sequelae.
Table 3 presents the incidence of general solicited symptoms.
The most frequently reported solicited symptom was mild
drowsiness, reported in all three vaccine groups. The only
occurrences of grade 3 solicited general symptoms were 5 cases
of fever greater than 39uC. None were judged to be related to the
study vaccines. Two cases of grade 3 fever were reported in the
MSP3-LSP 30 mg group after the second vaccine dose, one of
which was a malaria episode occurring on Day 6, while the second
case was associated with a gastroenteritis episode on Day 5. In the
Engerix B group, three cases were recorded, all due to malaria.
One participant in the MSP3-LSP 30 mg group experienced a
grade 3 unsolicited adverse events (hepatitis A) after the 2nd
Table 3. Incidence of general solicited adverse events according to vaccine groups.
Dose 1 Dose 2 Dose 3
Events Intensity
MSP3 (15 mg)
N=15
MSP3 (30 mg)
N=15
Engerix B
N=15
MSP3 (15 mg)
N=15
MSP3 (30 mg)
N=15
Engerix B
N=15
MSP3 (15 mg)
N=15
MSP3 (30 mg)
N=15
Engerix
B N=15
Fever
Any 0 2 2 1 3 5 0 4 2
Grade 1 0 0 0 1 1 2 0 3 1
Grade 2 0 2 1 0 0 1 0 1 1
Grade 3 0 0 1 0 2 2 0 0 0
Grade 3
related
0 0 0 0 0 0 0 0 0
Irritability
Any 0 1 0 1 0 0 0 3 0
Grade 1 0 1 0 1 0 0 0 3 0
Grade 2 0 0 0 0 0 0 0 0 0
Grade 3 0 0 0 0 0 0 0 0 0
Grade 3
related
0 0 0 0 0 0 0 0 0
Drowsiness
Any 0 5 1 5 3 1 2 4 5
Grade 1 0 5 0 5 3 1 2 4 5
Grade 2 0 0 0 0 0 0 0 0 0
Grade 3 0 0 0 0 0 0 0 0 0
Grade 3
related
0 0 0 0 0 0 0 0 0
Loss of appetite
Any 0 1 0 0 0 0 0 0 0
Grade 1 0 0 0 0 0 0 0 0 0
Grade 2 0 0 0 0 0 0 0 0 0
Grade 3 0 0 0 0 0 0 0 0 0
Grade 3
related
0 0 0 0 0 0 0 0 0
doi:10.1371/journal.pone.0007549.t003
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immunization (Table 4). The event was not judged to be related to
the vaccine.
Biological safety data did not show any important differences in
the numbers of participants with out-of-range values in the three
vaccine groups (Table 5). None of the out-of-range values were
judged to be related to vaccination, and none were considered
clinically important.
Humoral immune responses
Humoral immune response results are summarized in Figures 2
and 3. Total IgG, IgM and IgG1, IgG2, IgG3 and IgG4 subclasses
were measured at baseline (D0) and at one month intervals after
each vaccination (D28, D56 and D84). At baseline, the levels of
IgG antibody responses to MSP3-LSP were broadly similar in the
three groups. The total IgG response to MSP3-LSP appeared to
increase in both MSP3-LSP vaccine groups following vaccination
while no increase in anti-MSP3 antibody was observed in children
receiving the control (hepatitis B) vaccine. No marked changes in
antibody responses of the IgM class were seen in any of the vaccine
groups (Figure 2).
The cytophilic IgG (IgG1 and IgG3) and the non-cytophilic IgG
(IgG2 and IgG4) responses to MSP3-LSP are presented in
Figure 3. In both MSP3-LSP vaccine groups, cytophilic antibody
responses (IgG1 and IgG3) were markedly higher post-vaccination
than at baseline. In the control group (Engerix B), cytophilic IgG
antibody responses were similar pre- and post-vaccination. No
changes in IgG2 and IgG4 responses were evident in the control
arm. Responses post-vaccination appeared to have increased by
Day 84 in the MSP3-LSP 30 mg group, but these increases were
much less marked than those observed for IgG1 and IgG3
subclasses. In the 15 mg group any increases in IgG2 or IgG4
responses were small enough to be compatible with random
variation.
Discussion
This study was designed to evaluate the reactogenicity, safety
and immunogenicity of P. falciparum Merozoite Surface Protein-3
Long Synthetic Peptide (MSP 3-LSP) with aluminum hydroxide as
adjuvant in 12 to 24 month old children in Burkina Faso. The
study provides evidence of the safety and tolerability of MSP3-LSP
when given to young children with prior exposure to malaria in
Burkina Faso. We opted for a dose escalating design because this
was the first time this vaccine had been given to young children.
In comparison to the previous trials, MSP3-LSP appears to be more
reactogenic at the site of injection than the comparator Engerix-B
vaccine, with a higher proportion of MSP3-LSP recipients presenting
grade 3 local reactions (swelling and induration) [3–4;16–17]. With the
exception of localized symptoms at the site of injection which all
resolved spontaneously in a short time, post-vaccination follow up
Table 4. Incidence of unsolicited adverse events according to vaccine groups.
Events Intensity MSP3 (15 mg) N=15 MSP3 (30 mg) N=15 EngerixB N=15
Uncomplicated malaria a Any 35 26 35
Grade 1 30 23 30
Grade 2 5 3 5
Grade 3 0 0 0
Respiratory Infection Any 16 19 15
Grade 1 15 14 13
Grade 2 1 5 2
Grade 3 0 0 0
Diarrhea Any 3 5 1
Grade 1 3 4 1
Grade 2 0 1 0
Grade 3 0 0 0
Wound/dermatosis Any 9 3 4
Grade 1 7 2 2
Grade 2 2 1 2
Grade 3 0 0 0
Hepatitis A Any 0 2 1
Grade 1 0 1 1
Grade 2 0 0 0
Grade 3 0 1 0
Othersb Any 3 5 1
Grade 1 2 3 0
Grade 2 1 2 1
Grade 3 0 0 0
amalaria was define as fever (temperature .= 37.5) + any asexual parasitemia in absence of any evidence cause of fever recorded since the administration of the first
dose of the vaccine.
bOthers MSP3 (15 mg):Intoxication with oil, Stomatitis, splenomegaly; Others MSP3 (30 mg):Intoxication with oil, conjonctivis, fever without etiology.
Others EngerixB: fever without etiology.
doi:10.1371/journal.pone.0007549.t004
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recorded a similar incidence and intensity of general and unsolicited
symptoms among those receiving MSP3-LSP and those receiving the
Engerix B vaccine. The proportion of children who had biological
values outside the normal ranges for the measured parameters was
similar in all vaccine groups. These findings are consistent with
previous trials carried out in the same area in semi-immune adults
which showed MSP3-LSP with aluminum hydroxide to be safe and
well-tolerated [12].
Humoral immune responses (IgG, IgM and IgG subclasses (IgG1,
IgG2, IgG3 and IgG4)) were investigated at baseline (D0) and at one
month intervals after each dose (D28, D56 and D84). The MSP3-
LSP vaccine induced IgG antibody responses of which the strongest
were of cytophilic antibody sub-classes (IgG1 and IgG3). These two
classes of cytophilic antibodies have been reported to play a key role
both in vitro and in vivo in the monocyte mediated antibody-
dependent inhibition of parasite growth known as antibody
Table 5. Number of children with abnormal biological values after each vaccinationa.
Parameters Time point of assessment MSP3 (15 mg) N=15 MSP3 (30 mg) N=15 Engerix B N=15
RBC
6 days post dose 1 6 5 5
1 month post dose 1 5 6 5
1 month post dose 2 7 6 6
1 month post dose 3 5 3 4
WBC
6 days post dose 1 0 0 1
1 month post dose 1 2 1 1
1 month post dose 2 0 1 0
1 month post dose 3 0 1 0
Hb
6 days post dose 1 0 0 0
1 month post dose 1 1 0 0
1 month post dose 2 0 1 0
1 month post dose 3 1 2 1
Platelets
6 days post dose 1 0 1 0
1 month post dose 1 0 0 0
1 month post dose 2 0 0 0
1 month post dose 3 0 0 0
Creatinine
6 days post dose 1 0 0 0
1 month post dose 1 0 0 0
1 month post dose 2 0 0 0
1 month post dose 3 0 0 0
ASAT
6 days post dose 1 8 6 8
1 month post dose 1 10 12 12
1 month post dose 2 3 5 9
1 month post dose 3 6 5 6
ALAT
6 days post dose 1 1 0 1
1 month post dose 1 0 2 0
1 month post dose 2 0 0 2
1 month post dose 3 0 1 0
Total Bilirubin
6 days post dose 1 3 3 6
1 month post dose 1 2 2 1
1 month post dose 2 1 5 2
1 month post dose 3 0 1 1
aAll observed abnormal values were mild and not clinically significant.
doi:10.1371/journal.pone.0007549.t005
MSP3 LSP Safety/Immunogenicity
PLoS ONE | www.plosone.org 8 October 2009 | Volume 4 | Issue 10 | e7549
dependent cellular inhibition (ADCI) [3–4;16–17]. The two
cytophilic classes IgG1 and IgG3 induced in our study are the only
ones able to bind by their heavy chains to the Fc-gamma receptors
RIIa and RIIIa to induce the antiparasite, monocyte-dependent,
ADCI effect [18].
These cytophilic antibody responses, particularly anti-MSP3
IgG3, have been shown to be strongly associated with acquired
clinical protection in humans, [3–4;19–22]. Similar results were
seen in malaria naı¨ve, immunized Swiss volunteers where the
MSP3-LSP vaccine also generated cytophilic antibodies [10].
Non-cytophilic IgG (IgG2 and IgG4) antibody responses to
vaccination with MSP3-LSP were much less marked. The very low
levels or absence of non-cytophilic IgG2, IgG4 and IgM classes is a very
positive finding. Non-cytophilic antibodies could compete for the same
antigenic target as that used by ADCI which may inhibit the bridging
of merozoites to human monocytes by cytophilic antibodies. If this had
occurred it could potentially reduce the ability of cytophilic antibodies
to control parasite multiplication by the ADCI mechanism [20].
Humoral immune responses in young children with limited
exposure to natural P. falciparum contrast with those of our previous
Figure 2. Total IgG and IgM antibody responses to MSP3-LSP by vaccine group. Symbols represent individual value of antibody measured
by ELISA in a vaccine group and continuous line connects median values of arbitrary units of antibody responses to MSP3-LSP at different time points
by vaccine groups: m Full triangles and line in blue for MSP3-LSP (15 mg) group. N Full circles and line in red for MSP3-LSP (30 mg) group. x Cross
symbols and line in black for Engerix group.
doi:10.1371/journal.pone.0007549.g002
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trial conducted in adults. In the previous trial, no increase in anti-
MSP3 antibody concentrations was seen, probably because the
subjects already had high levels of pre-existing immunity resulting
from prior long standing natural exposure [12].
The rapid increase in antibodies after vaccination may indicate
that, although very young, the children have been primed by the
parasite antigen prior to vaccination. However, the generally low
level of anti-MSP3 specific responses in the control Engerix group
also suggests low overall exposure to malarial antigens in general,
and to MSP3 antigens in particular in the cohort of children
vaccinated.
Conclusion
These results demonstrate the short- and medium-term safety
and immunogenicity of the MSP3-LSP vaccine in children living
in an area characterized by stable seasonal malaria transmission in
Burkina Faso. The safety of both dose levels of MSP3 was
acceptable. However, a lower incidence of local reactogenicity was
observed with the control vaccine. The immunogenicity of MSP3-
LSP was demonstrated by the higher IgG responses observed in
both dose groups compared both to baseline levels and to the levels
in the group given the comparator vaccine. The profile of the
induced antibody responses favored the cytophilic subclasses (IgG1
Figure 3. Antibody responses of IgG subclasses to MSP3-LSP by vaccine group. Symbols represent individual value of antibody measured
by ELISA in a vaccine group and continuous line connects median values of arbitrary units of antibody responses to MSP3-LSP at different time points
by vaccine groups: m Full triangles and line in blue for MSP3-LSP (15 mg) group. N Full circles and line in red for MSP3-LSP (30 mg) group. x Cross
symbols and line in black for Engerix group.
doi:10.1371/journal.pone.0007549.g003
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and IgG3), and the higher dose of 30 mg appeared to induce
stronger responses that the 15 mg dose.
Given our results, we believe that the 30 mg dose of MSP3
should be evaluated in larger trials to investigate both immuno-
genicity and in vivo biological activity as demonstrated by, for
example, protection against malaria episodes or reduced severity
of malarial disease.
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